International Journal of Clinical Research

Objective To explore the clinical efficacy of a triple viable Bifidobacterium preparation in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D). Methods A total of 80 IBS-D patients admitted from May 2021 to May 2025 were randomly assigned to a control group (n=40) and an observation group (n=40). The control group received conventional symptomatic treatment, while the observation group was additionally given the triple viable Bifidobacterium preparation. Stool frequency, abdominal pain scores, quality of life, and recurrence rates were compared before and after treatment. Results The observation group showed significantly greater improvements in stool frequency and abdominal pain scores, higher quality of life scores, and lower recurrence rates compared with the control group (P<0.05). Conclusion The triple viable Bifidobacterium preparation can effectively relieve IBS-D symptoms, improve quality of life, and reduce recurrence, demonstrating high clinical application value.

Diarrhea-predominant irritable bowel syndrome; Triple viable Bifidobacterium preparation; Clinical efficacy; Quality of life